Clinical Trials Directory

Trials / Completed

CompletedNCT02557334

Effects of Freeze Dried Strawberry Powder Supplementation on Vascular Function and Blood Markers of Cardiovascular Risk

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
42 (actual)
Sponsor
Penn State University · Academic / Other
Sex
All
Age
35 Years – 65 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to evaluate the effects of freeze dried strawberry powder on LDL cholesterol, central and peripheral blood pressure, indices of arterial stiffness, and other lipid and lipoprotein concentrations. The investigators hypothesize that the bioactive compounds in freeze dried strawberry powder may elicit beneficial effects on LDL cholesterol, as well as blood pressure and arterial health.

Detailed description

The proposed study design is a 3-period randomized crossover dose-response study to evaluate the effect of freeze dried strawberry powder supplementation on LDL-C and vascular health. Research participants will be overweight or obese (BMI 25-39 kg/m\^2) but otherwise healthy adults with moderately elevated LDL-C (\>116 mg/dL or \>3.0mmol/L), blood pressure \<160/100 mmHg, total cholesterol below 273 mg/dL for men and below 284 mg/dL for women, and triglycerides below 350 mg/dL. Subjects will be randomly assigned to three supplementation periods: 1) low dose freeze dried strawberry powder (13 g/d); 2) high dose freeze dried strawberry powder (40 g/d); and 3) a placebo powder. Each powder will be provided for 4-6 weeks, separated by a 2-week washout period between treatment periods. Baseline and endpoint testing will include blood collection and vascular testing.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTLow Dose Strawberry Powder40 g composed of 13 g freeze dried strawberry powder + 27 g placebo powder
DIETARY_SUPPLEMENTHigh Dose Strawberry Powder40 g freeze dried strawberry powder
DIETARY_SUPPLEMENTPlacebo Powder40 g color and taste matched placebo powder

Timeline

Start date
2015-10-01
Primary completion
2019-05-01
Completion
2019-05-01
First posted
2015-09-23
Last updated
2023-08-18

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02557334. Inclusion in this directory is not an endorsement.